Business Overview & Strategy

  • The company operates as an integrated MedTech and Sustainable Infrastructure company with a 27-year legacy.
  • Strategic pillars include Innovation First, Quality & Compliance, Strategic Collaboration, and Scalable Execution.
  • Vision is to become a leading Indian MedTech and Sustainable Infrastructure company.
  • Mission focuses on making advanced healthcare diagnostics, medical technologies, and clean energy solutions accurate, affordable, and accessible.

Key Business Segments & Operations

Healthcare Segment (IVD, MedTech, Dialysis, Genomics):

  • Full portfolio includes IVD Reagents & Rapid Kits, TuBerculoScope, CRISPR Microbial Gene-Silencing Kit, Extra-Cellular Acidity Analyzer (ECAA), Breast Cancer Screening Kit, Oncodiagnoscope/Oncovision/Nasolight, Smart E-Clinic & Sehat Pods, Dozee Contactless ICU Monitoring, Renalyx Dialysis Machines, and Genome Testing (MyDNA).
  • 700+ distributors and 200+ enterprise clients across 15+ states with growing SAARC and US export footprint.
  • Cricket icon Rahul Dravid serves as Brand Ambassador across MedTech, Pathology and Genomics.

Renewable Energy & LED Segment:

  • Current secured order book of ~₹2,000 Cr from UPNEDA, BREDA, EESL, APDCL, Railways, Defence and the Navy.
  • Broader ₹3,000+ Cr pipeline in renewable energy.
  • Only firm holding the design formula for all Indian Navy warships' lighting; lit aircraft carrier INS Vikramaditya.
  • Committed to 500 MW of solar capacity over 7 years, with 100 MW+ already secured for the next two years.

Technological Innovations & IP

Renalyx AI Dialysis (85% owned subsidiary):

  • India's first indigenous AI-based Dialysis Machine with European CE Certification.
  • Patented technology with 7 years of clinical trials.
  • Reduces water use by 50%+ vs. conventional machines.
  • Cloud-connected platform with Renal Command Center for real-time CKD tracking.

AI Breast Screening (C-MET collaboration):

  • Non-radiative, painless thermal-mapping wearable for early detection.
  • Removes mammography radiation and discomfort; enables rural screening.

Oncodiagnoscope (BARC collaboration):

  • Portable optical spectroscopy device for oral cancer detection.
  • Provides 20-minute non-invasive result vs. multi-week biopsy cycles.
  • Trialled on 12,000+ patients with institutions including Tata Cancer Hospital.

Sickle Cell Testing:

  • High accuracy with sensitivity of 99% and specificity of 98%.
  • Fast turnaround time with results available within 30 minutes.
  • Partnership with Ministry of Tribal Affairs (MOTA) for screening tribal communities.
  • Exclusive IIT-Bombay license for point-of-care smartphone Sickle Cell diagnostics.

Manufacturing & Quality

  • In-house facility with single-roof production of rapid kits, reagents and analysers — only company in India with this CDSCO scope.
  • Gross margin profile: ~62% IVD, ~45% MedTech devices, ~12% Solar EPC (Company estimates).
  • Recent milestones include ICMR approval for Sickle Cell and Genome Testing, approval to manufacture veterinary blood-testing machines, and US FDA approval for Surgical Division.

Strategic Partnerships

  • IIT Bombay: Exclusive licence for point-of-care smartphone Sickle Cell diagnostics
  • BARC: Exclusive technology transfer for Oncodiagnoscope oral cancer detection
  • C-MET, Thrissur: AI-powered, radiation-free Breast Cancer Screening wearable
  • BITS Pilani: Multiplex PCR for Myeloid Leukemia (AML-M2)
  • MapMyGenome: Making genome testing accessible in India
  • Ministry of Tribal Affairs: Sickle cell screening across tribal communities
  • Philips/Cipla/Braithwaite: Distribution and technology partnerships across Solar, Lighting and Healthcare

Financial Projections (Source: Nuvama Wealth Management Limited)

Consolidated Financial Forecast (FY25 to FY29):

  • Revenue: ₹710 Cr → ₹2,638 Cr (3.7x growth, FY26–29 CAGR ~25.2%)
  • EBITDA: ₹81 Cr → ₹398 Cr (4.9x growth)
  • EBITDA Margin: 11.4% → 15.1% (+370 bps expansion)
  • Adjusted PAT: ₹46 Cr → ₹273 Cr (~6x growth)
  • Diluted EPS: ₹1.07 → ₹6.36 (~6x growth)
  • ROCE: 11% → 18% (+700 bps improvement)
  • Debt/Equity: 0.38x → 0.02x (near debt-free by FY29)

Segment Revenue Breakdown (FY25 → FY29E):

  • IVD + MedTech: ₹334 Cr → ₹1,467 Cr (Largest segment by FY29)
  • Lighting & Renewables: Combined ₹301 Cr → ₹915 Cr
  • Lighting: ₹225 Cr → ₹418 Cr
  • Solar/Renewables: ₹76 Cr → ₹496 Cr (6.5x growth)
  • Renalyx Health Systems: Launches FY27 at ₹62 Cr → ₹259 Cr by FY29 (EBITDA margin 18–25%)
  • Others (New Businesses): ₹192 Cr (FY27) → ₹233 Cr (FY29) at ~10% EBITDA margin

Renalyx Health Systems Specifics:

  • Unit Scale-Up: 1,266 units (FY27) → 2,697 (FY28) → 3,236 (FY29) (2.6x in 2 years)
  • Revenue streams: Outright Sale, Leasing, Pay-Per-Treatment (PPT), and AMC & Consumables
  • Consumables revenue: ₹9 Cr → ₹52 Cr
  • PPT revenue: ~₹20 Cr → ~₹130 Cr

Global Expansion

  • United States: Secured maiden $1,000,000 order for Contactless Remote Patient Monitoring (RPM) and AI Early Warning Systems (EWS).
  • Products are ISO 13485:2016, HIPAA and IEC 60601 compliant.
  • SAARC: Targeted diagnostic infrastructure deployment across Sri Lanka, Bangladesh and Nepal.
  • GCC & EU: Strategic dialogues initiated at Davos 2024 for MedTech distribution hubs.

Growth Roadmap & Catalysts

FY 2026–27:

  • Listing on NSE
  • Global footprint expansion in EU, USA & GCC countries
  • Full-fledged R&D team in India
  • FPO/Preferential Allotment - ₹500 Crs

FY 2027–28:

  • Wholetime manufacturing unit for Medtech
  • Reach 2,000 pathology labs and 1,000 Renal Care Units
  • Execute the IVD/MedTech demerger

FY 2028–29:

  • Cross ₹5,000 Cr consolidated group revenue
  • Achieve $3 billion group valuation

FY 2030:

  • Full operational presence across US, EU, GCC and SAARC
  • Established as a leading Indian MedTech conglomerate

ESG Initiatives

  • Environmental: Targeting Net-Zero carbon emissions across operations by 2035; 500+ MW planned solar capacity; Renalyx dialysis saves 50%+ water per session.
  • Social: Partnered with Ministry of Tribal Affairs for sickle cell screening; deploying e-Smart Clinics to remote and rural locations.
  • Governance: BSE-listed entity adhering to SEBI LODR; Independent board oversight.

Risks & Mitigations

  • Regulatory approval timelines: Mitigated by track record of securing approvals and in-house regulatory team.
  • Government payment cycles: Mitigated by diversified client base across states and PSUs; growing export/private mix.
  • Execution & scale-up risk: Mitigated by phased capex, experienced in-house project execution team.
  • Competitive intensity: Mitigated by cost leadership via in-house manufacturing plus exclusive institutional IP.

#Lord'sMarkIndustries #InvestorMeet #SEBIRegulation30 #GrowthOutlook #MedTech #Positive